These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19820272)

  • 1. Trials review: cardiovascular outcome with intensive glycemic control and implications for patients with type 2 diabetes.
    Brown SH; Abdelhafiz AH
    Postgrad Med; 2009 Sep; 121(5):31-41. PubMed ID: 19820272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk and glycemic control.
    Cheng AY; Leiter LA
    CMAJ; 2009 Apr; 180(9):907-8. PubMed ID: 19398731
    [No Abstract]   [Full Text] [Related]  

  • 3. Control of glycemia and other cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: data from the Adult Diabetes Control and Management.
    Sazlina SG; Mastura I; Ahmad Z; Cheong AT; Adam BM; Jamaiyah H; Lee PY; Syed-Alwi SA; Chew BH; Sriwahyu T
    Geriatr Gerontol Int; 2014 Jan; 14(1):130-7. PubMed ID: 23581598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose supply and insulin demand dynamics of antidiabetic agents.
    Monte SV; Schentag JJ; Adelman MH; Paladino JA
    J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive glycemic control and cardiovascular disease: an update.
    Brown A; Reynolds LR; Bruemmer D
    Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of glycated haemoglobin (HbA(1c)) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes.
    Yu PC; Bosnyak Z; Ceriello A
    Diabetes Res Clin Pract; 2010 Jul; 89(1):1-9. PubMed ID: 20494468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
    Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
    Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glycemic control and cardiovascular benefit: What do we know today?].
    Hanefeld M; Schönauer M; Forst T
    Dtsch Med Wochenschr; 2010 Feb; 135(7):301-7. PubMed ID: 20146161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensified glucose control in type 2 diabetes--whose agenda?
    Yudkin JS; Richter B; Gale EA
    Lancet; 2011 Apr; 377(9773):1220-2. PubMed ID: 21093903
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of intensive glycaemic control on cardiovascular outcomes.
    Hill D; Fisher M
    Diabetes Obes Metab; 2010 Aug; 12(8):641-7. PubMed ID: 20590740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus.
    Genuth S
    Ann Intern Med; 1996 Jan; 124(1 Pt 2):104-9. PubMed ID: 8554200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A
    Clin Ther; 2007 Jun; 29(6 Pt 1):1236-53. PubMed ID: 18036387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose control and vascular complications in veterans with type 2 diabetes.
    Duckworth W; Abraira C; Moritz T; Reda D; Emanuele N; Reaven PD; Zieve FJ; Marks J; Davis SN; Hayward R; Warren SR; Goldman S; McCarren M; Vitek ME; Henderson WG; Huang GD;
    N Engl J Med; 2009 Jan; 360(2):129-39. PubMed ID: 19092145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glycemic targets and cardiovascular morbi-mortality].
    Bordier L; Bauduceau B
    Presse Med; 2013 May; 42(5):855-60. PubMed ID: 23286961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypoglycemia and cardiovascular risk].
    Avogaro A
    G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):4S-12S. PubMed ID: 25623545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.
    Vijan S; Sussman JB; Yudkin JS; Hayward RA
    JAMA Intern Med; 2014 Aug; 174(8):1227-34. PubMed ID: 24979148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
    Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
    Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
    Macisaac RJ; Jerums G
    Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.